Literature DB >> 26771970

Expression of Proinflammatory Factors, Proangiogenic Factors and Endostatin in Patients with Heart Failure and Different Grades of Collateral Circulation Development.

Małgorzata Kobusiak-Prokopowicz1, Beata Jołda-Mydłowska1, Tomasz Grzebieniak1, Karol Początek1, Andrzej Mysiak1.   

Abstract

BACKGROUND: The process of collateral vessel maturation is stimulated by numerous factors affecting the endothelium and smooth muscle cells building the vessel wall. Looking for arteriogenesis stimulating factors means looking for a potential innovative heart failure treatment method in the patients unresponsive to traditional therapies.
OBJECTIVES: The purpose of this study was to assess the changes in serum concentrations of pro-inflammatory factor IL-6, growth factors FGF (FGFa, FGFb, FGFbH), HGF, VEGF and endostatin in heart failure patients in relation to the coronary collaterals development stage.
MATERIAL AND METHODS: This study included 22 patients with chronic heart failure NYHA II or III (mean age 62.5 ± 11.6 years) and 8 control patients (mean age 58.4 ± 10.7 years). Coronary angiography was performed and the presence and grade of collateral circulation was assessed by a four-level scale proposed by Rentrop and Cohen. The level of the studied factors was determined in the blood samples collected during the angiographic procedure.
RESULTS: The concentration of IL-6 was significantly higher in the heart failure patients than in the control group (p < 0.001) and in NYHA III vs. NYHA II patients (p < 0.02). Patients with heart failure and collaterals grade 1 or 2 exhibited higher serum concentrations of FGFbH (from p < 0.03 to p < 0.01). The serum VEGF level in NYHA III patients was significantly higher than in NYHA II individuals (from p < 0.03 to p < 0.01).
CONCLUSIONS: Higher levels of IL-6 and FGFbH were observed in patients with heart failure. Collaterals formation seems to be associated with the activation of pro-inflammatory factors, growth factors and endostatin.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26771970     DOI: 10.17219/acem/33811

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  4 in total

Review 1.  Endostatin in Renal and Cardiovascular Diseases.

Authors:  Mei Li; Zoran Popovic; Chang Chu; Bernhard K Krämer; Berthold Hocher
Journal:  Kidney Dis (Basel)       Date:  2021-09-09

2.  Evaluation of the effects of different treatment modalities on angiogenesis in heart failure patients with reduced/mid-range ejection fraction via VEGF and sVEGFR-1.

Authors:  Ismail Erturk; Kenan Saglam; Sadi Elasan; Musa B Aykan; Ramazan Acar; Fatih Yesildal; Fevzi N Aydin; Taner Ozgurtas
Journal:  Saudi Med J       Date:  2018-10       Impact factor: 1.484

3.  Blood Group Types O and Non-O Are Associated With Coronary Collateral Circulation Development.

Authors:  Savas Celebi; Ozlem Ozcan Celebi; Berkten Berkalp; Sinan Aydogdu; Basri Amasyali
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

4.  Serum Endostatin Is a Novel Marker for COPD Associated with Lower Lung Function, Exacerbation and Systemic Inflammation.

Authors:  Yanqiu Wu; Jiangyue Qin; Junyun He; Yongchun Shen; Hao Wang; Yanping Li; Qianglin Zeng; Jiajia Dong; Yunfei An; Shuguang Xiong; Mei Feng; Fuqiang Wen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-02-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.